| Fecha: |
2021 |
| Resumen: |
The Alzheimer's Disease (AD) is the most common form of dementia, characterized by memory loss, cognitive decline and neurodegeneration. It is caused principally by the accumulation of amyloid beta (Aß) peptide and Tau protein. Affecting over 35 million people worldwide, it is of an increased need the development of an early diagnostic based on the discovery of early, affordable and available non-invasive biomarkers (1). Recent evidence has demonstrated that the acetylation on the lysine 174 of Tau is an early critical pathological change to soluble Tau realized at the early stages in AD brains (Braak I-II), which leads to Tau accumulation and toxicity (2). However, the use of technologies with high sensibility will be required for its detection as this biomarker is expected to appear in low concentrations. For this reason, the current research project aims to validate the ac-K174 Tau as an early-diagnosis biomarker and to demonstrate its detection with a device proposal, as it could serve as a reliable biomarker for the detection of AD during early stages. |
| Derechos: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.  |
| Lengua: |
Anglès |
| Titulación: |
Biotecnologia [2500253] |
| Plan de estudios: |
Grau en Biotecnologia [815] |
| Documento: |
Treball final de grau ; Text |
| Materia: |
Alzheimer's disease ;
Alzheimer ;
Ac-k174 ;
Biomarcadors |
visitante ::
identificación
